

page 56312 a notice entitled "Filing of Plat of Survey; Rhode Island." In said notice was a plat depicting the survey of the Niles Land, designated Tract No. 8, a portion of the lands held in trust for the Narragansett Indian Tribe in Washington County, Rhode Island, accepted September 23, 2003.

The official filing of the plat is hereby stayed, pending consideration of all protests.

Dated: October 29, 2003.

Stephen D. Douglas,
Chief Cadastral Surveyor.

[FR Doc. 03-27667 Filed 11-3-03; 8:45 am]

BILLING CODE 4310-GJ-P

DEPARTMENT OF THE INTERIOR

Bureau of Reclamation

Glen Canyon Dam Adaptive Management Work Group (AMWG), Notice of Meetings

AGENCY: Bureau of Reclamation, Interior.

ACTION: Notice of public meetings.

SUMMARY: The Adaptive Management Program (AMP) was implemented as a result of the Record of Decision on the Operation of Glen Canyon Dam Final Environmental Impact Statement to comply with consultation requirements of the Grand Canyon Protection Act (Pub. L. 102-575) of 1992. The AMP provides an organization and process to ensure the use of scientific information in decision making concerning Glen Canyon Dam operations and protection of the affected resources consistent with the Grand Canyon Protection Act. The AMP has been organized and includes a federal advisory committee (AMWG), a technical work group (TWG), a monitoring and research center, and independent review panels. The TWG is a subcommittee of the AMWG and provides technical advice and information for the AMWG to act upon.

Date and Location: The AMWG will conduct the following public meeting:

Phoenix, Arizona—January 7 to January 8, 2004. The meeting will begin at 9:30 a.m. and conclude at 5 p.m. on the first day and will begin at 8 a.m. and conclude at 2 p.m. on the second day. The meeting will be held at the Bureau of Indian Affairs—Western Regional Office, 2 Arizona Center, 400 N. 5th Street, Conference Rooms A and B (12th Floor), Phoenix, Arizona.

Agenda: The purpose of the meeting will be to discuss the FY 2005 budget, environmental compliance required on the temperature control device, current and potential future temperatures of

Glen Canyon Dam releases, humpback chub comprehensive plan and peer review, long-term monitoring plan development, update on GCMRC reorganization, review of AMWG Charter and Operating Procedures, experimental flows, basin hydrology, and other administrative and resource issues pertaining to the AMP.

Date and Location: The TWG will conduct the following public meeting: Phoenix, Arizona—November 12 to November 13, 2003. The meeting will begin at 9:30 a.m. and conclude at 5 p.m. on the first day and will begin at 8 a.m. and conclude at noon on the second day. The meeting will be held at the Bureau of Indian Affairs—Western Regional Office, 2 Arizona Center, 400 N. 5th Street, Conference Rooms A and B (12th Floor), Phoenix, Arizona.

Agenda: The purpose of the meeting will be to discuss the FY 2005 budget, NEPA requirements for FY 2004 and FY 2005 actions, flow modifications, update on GCMRC reorganization, Cultural Programmatic Agreement Program, FY 2004 project reviews, environmental compliance, and other administrative and resource issues pertaining to the AMP.

To allow full consideration of information by the AMWG, written notice must be provided to Dennis Kubly, Bureau of Reclamation, Upper Colorado Regional Office, 125 South State Street, Room 6107, Salt Lake City, Utah, 84138; telephone (801) 524-3715; faxogram (801) 524-3858; e-mail at dkubly@uc.usbr.gov (5) days prior to the meeting. Any written comments received will be provided to the AMWG members prior to the meeting.

FOR FURTHER INFORMATION CONTACT: Dennis Kubly, telephone (801) 524-3715; faxogram (801) 524-3858; or via e-mail at dkubly@uc.usbr.gov.

Dated: October 24, 2003.

Dennis Kubly,
Chief, Adaptive Management Group,
Environmental Resources Division, Upper
Colorado Regional Office.

[FR Doc. 03-27628 Filed 11-3-03; 8:45 am]

BILLING CODE 4310-MN-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA #249]

Controlled Substances: Proposed Aggregate Production Quotas for 2004

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of proposed year 2004 aggregate production quotas.

SUMMARY: This notice proposes initial year 2004 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).

DATES: Comments or objections must be received on or before November 25, 2003.

ADDRESSES: Send comments or objections to the Acting Deputy Administrator, Drug Enforcement Administration, Washington, DC 20537, Attn.: DEA Federal Register Representative (CCR).

FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by § 0.100 of title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator, pursuant to § 0.104 of title 28 of the Code of Federal Regulations.

The proposed year 2004 aggregate production quotas represent those quantities of controlled substances that may be produced in the United States in 2004 to provide adequate supplies of each substance for: The estimated medical, scientific, research, and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.

In determining the proposed year 2004 aggregate production quotas, the Acting Deputy Administrator considered the following factors: Total actual 2002 and estimated 2003 and 2004 net disposals of each substance by all manufacturers; estimates of 2003 year-end inventories of each substance and of any substance manufactured from it and trends in accumulation of such inventories; product development requirements of both bulk and finished dosage form manufacturers; projected demand as indicated by procurement quota applications filed pursuant to § 1303.12 of title 21 of the Code of Federal Regulations; and other pertinent information.

Pursuant to part 1303 of title 21 of the Code of Federal Regulations, the Acting